1. Home
  2. NTRA vs HUM Comparison

NTRA vs HUM Comparison

Compare NTRA & HUM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$229.36

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Logo Humana Inc.

HUM

Humana Inc.

HOLD

Current Price

$257.05

Market Cap

28.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRA
HUM
Founded
2003
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.0B
28.2B
IPO Year
2015
1993

Fundamental Metrics

Financial Performance
Metric
NTRA
HUM
Price
$229.36
$257.05
Analyst Decision
Strong Buy
Buy
Analyst Count
15
17
Target Price
$238.20
$296.94
AVG Volume (30 Days)
1.2M
1.4M
Earning Date
11-06-2025
02-10-2026
Dividend Yield
N/A
1.37%
EPS Growth
N/A
N/A
EPS
N/A
10.68
Revenue
$2,116,676,000.00
$126,362,000,000.00
Revenue This Year
$33.18
$10.81
Revenue Next Year
$16.81
$11.75
P/E Ratio
N/A
$24.25
Revenue Growth
38.17
9.87
52 Week Low
$125.38
$206.87
52 Week High
$246.90
$315.35

Technical Indicators

Market Signals
Indicator
NTRA
HUM
Relative Strength Index (RSI) 52.01 50.15
Support Level $227.89 $254.38
Resistance Level $237.04 $259.25
Average True Range (ATR) 5.07 7.16
MACD -1.57 -0.20
Stochastic Oscillator 49.47 12.98

Price Performance

Historical Comparison
NTRA
HUM

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About HUM Humana Inc.

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Share on Social Networks: